| Year of Transplant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | ||
| Transplants | 4,188 | 4,516 | 4,751 | 4,997 | 5,195 | 5,332 | 5,673 | 6,170 | 6,443 | 6,650 | |
| Tx with Follow-up Immunosuppression Info | 3,182 | 3,479 | 3,641 | 3,890 | 4,091 | 4,305 | 4,569 | 4,940 | 5,058 | 5,297 | |
| Corticosteroids | Any in Category | 95.0% | 93.0% | 89.3% | 90.5% | 89.4% | 87.2% | 78.5% | 75.4% | 75.4% | 71.8% |
| Steroids | 95.0% | 93.0% | 89.3% | 90.5% | 89.4% | 87.2% | 78.5% | 75.4% | 75.4% | 71.8% | |
| Cyclosporine | Any in Category | 39.8% | 33.4% | 30.4% | 23.4% | 18.4% | 14.0% | 11.8% | 11.6% | 10.4% | 9.9% |
| Cyclosporin | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | |
| Sandimmmune | 5.7% | 7.0% | 7.0% | 5.4% | 3.7% | 2.0% | 0.7% | 0.9% | 1.1% | 1.2% | |
| Neoral | 34.1% | 26.3% | 23.3% | 17.2% | 13.3% | 9.8% | 8.9% | 9.2% | 7.8% | 6.7% | |
| Gengraf | 0.0% | 0.0% | 0.1% | 0.5% | 1.3% | 2.0% | 1.8% | 1.3% | 1.3% | 1.7% | |
| Eon | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.2% | 0.3% | 0.2% | 0.1% | 0.2% | |
| Tacrolimus | Any in Category | 66.3% | 73.4% | 76.7% | 84.1% | 89.0% | 90.5% | 90.5% | 89.7% | 91.6% | 90.8% |
| Tacrolimus | 66.3% | 73.4% | 76.7% | 84.1% | 89.0% | 90.5% | 90.5% | 89.7% | 91.6% | 90.8% | |
| Antimetabolites | Any in Category | 44.4% | 40.3% | 49.3% | 52.2% | 53.5% | 53.7% | 55.1% | 59.0% | 66.3% | 69.7% |
| Mycophenolate Mofetil | 25.9% | 29.7% | 40.8% | 46.2% | 48.8% | 49.3% | 52.4% | 55.5% | 62.2% | 64.3% | |
| Mycophenolate Sodium | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 2.9% | 4.4% | |
| Azathioprine | 18.2% | 10.5% | 8.3% | 5.9% | 4.6% | 4.3% | 2.7% | 3.0% | 1.2% | 1.0% | |
| Leflunomide | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Cytoxan | 0.3% | 0.0% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| mTOR Inhibitors | Any in Category | 0.0% | 1.2% | 3.2% | 15.1% | 16.6% | 13.8% | 12.2% | 14.1% | 13.8% | 11.9% |
| Sirolimus | 0.0% | 1.2% | 3.1% | 15.1% | 16.6% | 13.8% | 12.2% | 14.1% | 13.8% | 11.9% | |
| Everolimus | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |